Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
C5 Complement Inhibitors Market Size And Revenue Outlook Through 2030
The c5 complement inhibitors market has seen rapid expansion in recent years. It is anticipated to grow from $7.84 billion in 2025 to $8.93 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.9%. The market’s past growth can be attributed to several factors, including the approval of first-in-class complement inhibitors, a rise in the diagnosis of rare hematological disorders, improved clinical understanding of complement pathways, the expansion of specialty treatment centers, and strong development pipelines for biologics.
The c5 complement inhibitors market size is anticipated to experience significant expansion in the coming years. It is projected to reach $14.93 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 13.7%. This growth over the forecast period is propelled by factors such as the rising incidence of autoimmune and rare diseases, the broadening of personalized medicine approaches, an expanding pipeline of next-generation inhibitors, an increase in biologics manufacturing capacity, and supportive regulatory pathways designed for orphan drugs. Important trends during this period involve the growing adoption of targeted immunotherapies, increased utilization in rare complement-mediated disorders, a rising preference for long-acting formulations, the development of combination treatment strategies, and a heightened focus on early diagnosis and intervention.
Get A Free Sample Report With In-Depth Market Insights:
C5 Complement Inhibitors Market Growth Catalysts And Demand Drivers
The rising occurrence of chronic illnesses is anticipated to fuel the expansion of the C5 complement inhibitors market moving forward. These are enduring medical conditions that progress slowly and persist over time, often necessitating continuous medical attention and management to prevent complications. The increasing prevalence of chronic diseases is primarily attributed to lifestyle changes such as poor diet, physical inactivity, smoking, and stress, which contribute to long-term health deterioration. C5 complement inhibitors benefit patients with chronic diseases by blocking the excessive activation of the complement system, thereby reducing inflammation, preventing tissue damage, and improving disease outcomes in conditions like PNH, aHUS, and other complement-mediated disorders. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based non-profit organization, more than 9.5 million people were living with type 1 diabetes in 2024, including 1.9 million children and adolescents under 20. The global diabetes population is projected to ascend to 853 million by 2050. Hence, the growing prevalence of chronic diseases is driving the growth of the C5 complement inhibitors market.
C5 Complement Inhibitors Market Breakdown By Product Type And Application
The c5 complement inhibitors market covered in this report is segmented –
1) By Product: Long Acting C5 Inhibitors, Short Acting C5 Inhibitors
2) By Drug: Eculizumab, Ravulizumab, Other Drugs
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
5) By Application: Paroxysmal Noctural Hemoglobuinuria, Atyptical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Neuromyelitis Optics Spectrum Disorder, Other Applications
Subsegments:
1) By Long Acting C5 Inhibitors: Crovalimab, Pozelimab, Tesidolumab, Other Long-Acting C5 Inhibitors
2) By Short Acting C5 Inhibitors: Zilucoplan, Cemdisiran, Nomacopan, Other Short-Acting C5 Inhibitors
C5 Complement Inhibitors Market Trends Shaping Long-Term Demand
Leading companies in the C5 complement inhibitors market are dedicated to developing innovative treatments, including self-administered C5 inhibitors, to extend therapeutic options for generalized myasthenia gravis. Such a self-administered C5 inhibitor functions as a targeted therapeutic agent, blocking the complement C5 protein to mitigate inflammation and immune-mediated damage, and is designed for patient self-use in treating conditions like paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. An example of this advancement occurred in October 2023 when Union Chimique Belge (UCB) SA, a Belgium-based biopharmaceutical company, announced the Food and Drug Administration (FDA), a US-based government regulatory agency, had approved Zilbrysq (zilucoplan) for adults with generalized myasthenia gravis (gMG). This specific approval targets patients identified as anti-acetylcholine receptor (AChR) antibody-positive, a common manifestation of the disease. Zilbrysq itself is a self-administered, once-daily, subcutaneous C5 complement inhibitor, presenting a new treatment alternative for gMG patients. This regulatory clearance strengthens UCB’s neurology portfolio, broadening the available treatment selections for those with autoimmune neuromuscular disorders.
C5 Complement Inhibitors Market Company Landscape And Competitive Strategy
Major companies operating in the c5 complement inhibitors market are AstraZeneca plc, F. Hoffmann-La Roche AG, Chugai Pharmaceutical Co. Ltd., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Omeros Corporation, Dianthus Therapeutics Inc., Akari Therapeutics Plc, Regeneron Pharmaceuticals Inc., UCB Pharma SA, Astellas Pharma Inc., InflaRx NV, Alexion Pharmaceuticals Inc., Ra Pharmaceuticals Inc., ChemoCentryx Inc., Annexon Biosciences Inc., Iveric Bio Inc., Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Inc.
View The Full C5 Complement Inhibitors Market Report:
C5 Complement Inhibitors Market Top Region By Revenue And Market Share
North America was the largest region in the C5 complement inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c5 complement inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
